Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 46708-556

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 46708-556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 Tablets (Sacubitrilvalsartan 24 26 mg)

Label for sacubitril and valsartan tablets, film-coated, with strength 24 mg/26 mg. The label indicates 60 tablets per bottle and is manufactured by Alembic Pharmaceuticals Limited. It includes storage instructions and a barcode, along with the NDC 46708-556-60.*

FDA Label Image

60 Tablets (Sacubitrilvalsartan 49 51 mg)

Label for sacubitril and valsartan tablets, film coated, oral dosage form, containing 49 mg sacubitril and 51 mg valsartan per tablet. The package holds 60 tablets. Manufactured by Alembic Pharmaceuticals Limited. NDC 46708-557-60. Storage instructions and dosage information are also present.*

FDA Label Image

Figure 7 (Sacubitrilvalsartan 7 Figure)

A dual-panel line chart comparing the hazard ratio of sacubitril and valsartan versus enalapril in the PARADIGM-HF study (left panel), and sacubitril and valsartan versus valsartan in the PARAGON-HF study (right panel). The x-axis represents left ventricular ejection fraction at screening (%) and the y-axis shows hazard ratio with 95% confidence intervals indicated by dashed lines.*

FDA Label Image

60 Tablets (Sacubitrilvalsartan 97 103 mg)

Sacubitril and Valsartan Tablets, 97 mg/103 mg, film-coated oral tablets labeled for prescription use. The label indicates a package quantity of 60 tablets and is manufactured by Alembic Pharmaceuticals Limited, with storage instructions and barcode included.*

FDA Label Image

Sacubitrilvalsartan-fig-2 (Sacubitrilvalsartan Fig 2)

A comparative plot showing geometric mean ratios and 90% confidence intervals for AUC and Cmax of sacubitril (LBQ657) and valsartan across different population subgroups, including variations in renal and hepatic impairment, age, sex, and race. The graph displays change relative to reference values for each subgroup.*

FDA Label Image

Figure 1 (Sacubitrilvalsartan Fig1)

A geometric mean ratio and 90% confidence interval plot showing the effect of sacubitril and valsartan on the pharmacokinetics (AUC and Cmax) of various coadministered drugs. The x-axis represents change relative to reference values, with plotted data points for furosemide, warfarin, digoxin, carvedilol, levonorgestrel, ethinyl estradiol, amlodipine, HCTZ, metformin, atorvastatin, and sildenafil.*

FDA Label Image

Figure 3 (Sacubitrilvalsartan Fig3)

Three Kaplan-Meier survival curves showing time to cardiovascular (CV) death or heart failure hospitalizations in the PARADIGM-HF study comparing sacubitril and valsartan versus enalapril. The graphs illustrate cumulative failure rates over days since randomization, with sacubitril and valsartan consistently showing lower rates than enalapril across all measured outcomes.*

FDA Label Image

Figure 4 (Sacubitrilvalsartan Fig4)

A forest plot chart comparing hazard ratios for sacubitril and valsartan versus enalapril across various subgroups like age, gender, weight, race, region, NYHA class, GFR, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP, hypertension, use of ACE inhibitors or ARBs, aldosterone antagonists, hospitalization history, heart failure cause, ICD presence, and more. The plot depicts the confidence intervals for each subgroup indicating comparative effectiveness.*

FDA Label Image

Figure 6 (Sacubitrilvalsartan Figur6)

A forest plot comparing the efficacy of sacubitril and valsartan tablets versus valsartan alone across various subgroups including age, sex, race, region, diabetic status, and baseline clinical characteristics. The plot shows point estimates and 95% confidence intervals for rate ratios, indicating the relative benefit of sacubitril and valsartan over valsartan.*

FDA Label Image

Figure 5 (Sacubitrilvalsartan Figure5)

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF' comparing mean number of events per 100 patients over time (days since randomization) between Sacubitril and Valsartan combination therapy and Valsartan alone. The x-axis represents time in days up to 1440, and the y-axis shows mean events up to 60. Two lines are plotted, with Sacubitril and Valsartan consistently below Valsartan alone, indicating fewer events.*

FDA Label Image

Structure (Sacubitrilvalsartan Str)

Chemical structure diagram of the active ingredients sacubitril and valsartan, showing their molecular arrangements including functional groups and bonding patterns.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.